Company Overview

Corporate Information

Business Model (Strengths and Competitive Advantages)

Hormone-related expertise cultivated since our founding

Guided by our corporate philosophy of “Contribute toward the improvement of people’s health and progress in society through the development of innovative products,” the ASKA Pharmaceutical Holdings Group aims to grow and develop as a company that is trusted by society through its medical-related businesses, including its core pharmaceutical business, its animal health business, and the testing business.
We perform research and development of pharmaceuticals using the hormone-related expertise we have cultivated since our founding, with particular strength in healthcare for women and endocrine hormones. We are creating unique synergies through such means as taking pharmaceuticals originally made for humans and adapting them for use in animals. Another one of our strengths is in testing technologies that enable microdetermination. In each area, hormones are the foundation for conducting our business.

Healthcare for women
  • A leading company in the Ob/Gyn field
  • Top sales in the Ob/Gyn field (In-house estimate for FY2023)
Endocrine hormones
  • Endocrine hormone R&D Over 100 years
  • A leading company in the thyroid field
  • 95% share of domestic market
Animal Health
  • Large market presence in the livestock field thanks to lineup of mainstay breeding hormone preparations
  • Products addressing untapped needs in the companion animal market
  • Contribution to greater uptake of low-protein feed through full lineup of feed-use amino acids
Microdetermination (non-invasive testing)
  • High-sensitivity measurement using liquid chromatography-tandem mass spectrometry (LC-MS/MS)
  • Multi-item simultaneous steroid hormone measurement
  • Ultra-high-sensitive estrogen measurement
  • Measurement of thyroid-related substances
  • Measurements using non-invasive samples

Consolidated Sales

Consolidated Sales
連結売上高アイコン

64.1

billion yen

(FY2024)

  • ASKA Pharmaceutical 56.6 billion yen
    (Pharamaceutical business)
  • ASKA Animal Health 7.2 billion yen
    (Animal health business)
  • ASKA Pharma Medical 0.2 billion yen
    (Testing business)

Core Information

(As of June 25, 2024)

Company name ASKA Pharmaceutical Holdings Co., Ltd.
Address
5-1, Shibaura 2-Chome, Minato-ku, Tokyo 108-8532, Japan
Tel: +81-3-5484-8845
Established April 1, 2021
Capital ¥1,197.9 million (as of March 31, 2020)
Business segments Business management of group companies and related businesses
Representative Takashi Yamaguchi
President, Representative Director
Executives Please see the list of Executives.
Number of Employees (Consolidated) 762 (127)*
URL https://www.aska-pharma-hd.co.jp/english/
Corporate Profile Download
Audit Firm Seiyo Audit Corporation
Book Runner Mitsubishi UFJ Morgan Stanley Securities Co., Ltd.
Main Bank MUFG Bank / Sumitomo Mitsui Banking Corporation / Mitsubishi UFJ Trust and Banking Corporation

*Number of employees is the number of full-time employees who actually work as of March 31, 2024. Figures in parentheses represent the average number of temporary employees during the year and are not included in the number of full-time employees. The number of employees includes those who concurrently work at our Group companies.